Related Experiment Video
Updated: Jun 18, 2025

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection
Published on: November 7, 2018
[Chronic HBV and HDV infection]
Insights
Chronic hepatitis B virus (HBV) infection affects 0.5% of Germany's population. Early antiviral therapy can prevent liver disease progression, though a cure remains elusive.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Context:
- Chronic hepatitis B virus (HBV) infection impacts approximately 0.5% of the German population.
- Untreated chronic HBV can lead to severe liver conditions like liver cirrhosis and hepatocellular carcinoma (HCC).
- Hepatitis D virus (HDV) co-infection occurs in about 5% of chronic HBV cases, significantly accelerating liver disease progression.
Purpose:
- To summarize the epidemiology and clinical implications of chronic hepatitis B virus (HBV) and HBV/HDV co-infection.
- To highlight the current therapeutic landscape, including the advent of bulevirtide for HBV/HDV co-infection.
Summary:
- Chronic HBV infection affects a notable portion of the German population, with potential for severe liver disease progression.
- HBV/HDV co-infection presents a more aggressive disease course, leading to cirrhosis in approximately 50% of patients within 5-10 years.
- Bulevirtide, a cell entry inhibitor, has been available since 2020 as a targeted therapy for HBV/HDV co-infection, offering a new treatment option.
Impact:
- Early diagnosis and antiviral therapy are crucial for managing chronic HBV infection and preventing advanced liver disease.
- The availability of bulevirtide represents a significant advancement in treating severe HBV/HDV co-infection.
- Further research is needed to achieve a definitive cure for chronic HBV infection.
Abstract:
About 0,5% of the population in Germany has a chronic hepatitis B virus (HBV) infection. Untreated, chronic HBV infection can progress to liver cirrhosis and hepatocellular carcinoma (HCC). If diagnosed early, antiviral therapy can effectively prevent liver disease progression, but a cure is currently hardly achievable. About 5% of those chronically infected with HBV are also co-infected with the hepatitis D virus (HDV). HBV/HDV co-infection leads to liver cirrhosis in approximately 50% of patients within 5-10 years. Since 2020, the cell entry inhibitor bulevirtide is available as a specific therapy for HBV/HDV co-infection.
Related Concept Videos
Retrovirus Life Cycles
Mechanisms of Retrovirus-induced Cancers
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Retroviruses
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...

